Amicus Therapeutics, Inc.
FOLD
Clasificación en acciones
#3707
Amicus Therapeutics, Inc. is a biotechnology firm dedicated to the discovery,... Amicus Therapeutics, Inc. is a biotechnology firm dedicated to the discovery, development, and delivery of medical treatments for rare conditions. Its primary commercial offering is Galafold, an orally administered precision medicine designed for adult patients with a confirmed diagnosis of Fabry disease, specifically those exhibiting an amenable galactosidase alpha gene variant as identified by in vitro assay data. The company's pipeline also includes several investigational therapies: AT-GAA, an innovative treatment strategy for Pompe disease; various enzyme replacement therapies aimed at Pompe diseases; and AT-GTX-502, an AAV serotype gene therapy for CLN3. The latter is currently undergoing Phase 1/2 clinical studies to evaluate the safety and efficacy of a single intrathecal administration in patients with CLN3. Additionally, Amicus is exploring therapeutic approaches related to CDKL5, a gene on the X-chromosome that encodes a protein essential for regulating proper brain development. Amicus maintains strategic collaborations and licensing arrangements with prominent entities such as Nationwide Children's Hospital, the University of Pennsylvania, and GlaxoSmithKline. The company was founded in 2002 and is based in Philadelphia, Pennsylvania.
Precio por acción
$14.49
Última sincronización: 2026-04-27
Capitalización bursátil
$4.55B
Cambio (1 día)
0.00%
Cambio (1 año)
71.68%
País
US
Comercio Amicus Therapeutics, Inc. (FOLD)
Categoría
Healthcare
Ratio P/B de Amicus Therapeutics, Inc. (FOLD)
Ratio P/B al October 2026 TTM: 16.33
Según los informes financieros más recientes y el precio de las acciones de Amicus Therapeutics, Inc., el ratio P/B actual (TTM) es 16.33. Al final de 2023, el ratio P/B era 26.15.
Historial del ratio P/B de Amicus Therapeutics, Inc. desde 2003 hasta 2026
Ratio P/B al final de cada año
| Año | Ratio P/B | Cambiar |
|---|---|---|
| 2026 (TTM) | 16.33 | 10.47% |
| 2024 | 14.78 | -43.49% |
| 2023 | 26.15 | -8.84% |
| 2022 | 28.68 | 181.23% |
| 2021 | 10.20 | -51.13% |
| 2020 | 20.87 | 324.64% |
| 2019 | 4.92 | -5.30% |
| 2018 | 5.19 | -17.01% |
| 2017 | 6.25 | 237.21% |
| 2016 | 1.85 | -39.50% |
| 2015 | 3.07 | -39.53% |
| 2014 | 5.07 | 92.44% |
| 2013 | 2.63 | 49.32% |
| 2012 | 1.76 | -56.10% |
| 2011 | 4.02 | 100.18% |
| 2010 | 2.01 | 60.55% |
| 2009 | 1.25 | -50.51% |
| 2008 | 2.53 | 83.43% |
| 2007 | 1.38 | -1,105.40% |
| 2006 | -0.14 | -17.07% |
| 2005 | -0.17 | 0.00% |
| 2004 | 0.00 | -100.00% |
| 2003 | -0.84 | 0.00% |
Ratio P/B de empresas similares o competidoras
| Empresa | Ratio P/B | Diferencia del ratio P/B | País |
|---|---|---|---|
| 6.251 | -61.72% |
US
|
|
| 13.2547 | -18.82% |
US
|
|
| 4.208 | -74.23% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -62.14% |
NL
|
